China Biopharma Profit Climbs 20 Percent In H1
This article was originally published in PharmAsia News
Statistics from the market research agency WIND point out that in the first six months of this year, the accelerated profits of 126 Chinese biopharma companies approached $14.852 billion, jumping 19.98%. Their net profits rose 20.75% to $12.233 billion
You may also be interested in...
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.
The current pandemic has accelerated the US FDA’s perspective on conducting remote clinical trials. The agency has published an emergency guidance to allow sponsors to continue their work, which a former FDA official says is an indication of where the agency is headed post-COVID-19.
Facing ongoing shortages, the US FDA is allowing most surgical masks to be used as personal protective equipment under a new emergency use authorization.